FDA approves Novartis’ Itvisma for older patients with spinal muscular atrophy

Novartis has secured FDA approval for a new version of its one-time gene therapy for spinal muscular atrophy (SMA) that it says could benefit a much broader swathe of patients. The Swiss drugmaker